1[1]The Scandinavian Simvastatin Survival Group.Randomized trial of chole-sterol lowering in 4 444 patients with coronary heart disease:The Scandinavian Simvastatin Survival Study (4S)[J].Lancet,1994,344:1383-1389.
2[2]Shepherd J,Cobbe S M,Ford I,et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia[J].N Engl J med,1995,333(20):1301-1307.
3[3]Jukema J W,Onbehalf to the REGRESS study group,InterUniversity Cardiology.Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels.The Regression Growth Evaluation Statin Study (REGRESS)[J].Circulation,1995,91:2528.
4[4]Aikawa M,Rabkin E,Voglic S J,et al.Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma:a potential mechanism of lesion stabilization[J].Circulation,1998,95:2433-2444.
5[5]MAAS Investigators.Effects of simvastatin on coronary atheroma:the multicentre anti-atheroma study (MAAS)[J].Lancet,1994,344:633.
6[6]Crouse J R.Pravastatin,Lipids and atherosclerosis in the carotid arteries (PLAC-Ⅱ)[J].Am J Cardiol,1995,75:455-459.
7Gelermajer DS,Sorensen KE,Bull C,et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk of factors and their interaction[J]. J Am Coll Cardiol,1994,24:1468-1474.
8Doi H,Kugiyama K,Ohgushi M,et al. Remnants of chylomicron and very low density lipoprotein impair endothelium-depended vasorelaxation[J]. Atherosclerosis,1998,137:341-349.
9Treasure CB,Klein L, Weinteraub WS,et al. Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease[J]. N Engl J Med,1995,332:481-487.
10Voger RA,Corretti MC,Plotmick GD,et al. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men[J]. Am J Cardiol,1996,77:37-40.
